Company Overview
biote Corp. operates within the healthcare sector, specifically focusing on the medical care facilities industry through its practice-building business in the hormone optimization space. The company trains physicians and nurse practitioners to deliver hormone optimization services using bioidentical hormone replacement pellet therapy for men and women experiencing hormonal imbalances, while also offering the Biote Method. This operational model positions the firm as a specialized provider in a niche medical segment, distinguishing it from general hospital operators. The company holds a market capitalization of $58.22M and reports annual revenue of $192.22M based on trailing twelve-month figures, employing a workforce of 223 individuals. These valuation and revenue metrics indicate that the company functions as a mid-sized entity within its niche, possessing a substantial revenue base relative to its market cap which suggests a high valuation multiple or significant intangible value not fully captured by the current equity price.
Financial Health
The company reported revenue of $192.22M, net income of $27.05M, and EBITDA of $37.54M for the trailing twelve-month period. The gap between the $192.22M revenue and the $27.05M net income reveals a cost structure where operating expenses, taxes, and interest consume approximately 86% of top-line revenue before reaching the bottom line. Despite the high expense ratio, the business generates $13.27M in free cash flow, which provides the company with financial flexibility to fund operations, maintain its training programs, or manage debt obligations without immediate reliance on external financing. The gross margin stands at 71.5%, indicating strong pricing power or low cost of goods sold typical of service-based or specialized therapy models. The operating margin is 9.4%, reflecting the overhead costs associated with training and practice support, while the profit margin reaches 14.1%, demonstrating that the company retains a significant portion of revenue after all expenses. On the balance sheet, the company holds $24.12M in cash against $109.92M in debt, resulting in a debt-to-equity ratio that is listed as N/A, suggesting the capital structure is heavily weighted toward liabilities relative to shareholder equity. The current ratio of 1.22 indicates that the company has sufficient short-term assets to cover its short-term liabilities, though with limited liquidity buffer above the 1.0 threshold. Return on assets is 19.1%, which suggests efficient utilization of assets to generate income, while return on equity is listed as N/A, preventing a direct assessment of shareholder return efficiency in the traditional sense.
Valuation Assessment
The stock carries a P/E ratio of 1.78 on a trailing twelve-month basis and a forward P/E of 2.32, implying that the market expects earnings to decline slightly or remain stagnant rather than grow significantly in the near future. The price-to-book ratio is -0.69, which indicates that the market values the company at a negative multiple of its book value, a situation often seen in firms with significant debt or where book value is not a relevant metric for valuation. The price-to-sales ratio is 0.30, suggesting the market prices the revenue at a fraction of its total, while the EV/EBITDA stands at 3.58, offering an enterprise value perspective relative to cash earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week low of $1.27 and a 52-week high of $4.75, meaning the current trading price sits at a specific point within this range that reflects recent market sentiment and volatility. With a beta of 1.14, the stock exhibits price volatility that is 14% higher than the broader market, indicating that price movements in biote Corp. will likely amplify those of the overall index during periods of market stress or rally.
Growth & Income
The company experienced a revenue growth rate of -6.9% year-over-year and an earnings growth rate of -36.7% year-over-year for the most recent period. Earnings are declining at a much faster rate than revenue, as evidenced by the disparity between the -6.9% revenue contraction and the -36.7% earnings contraction, which implies that cost pressures or margin compression are disproportionately affecting profitability compared to top-line stability. As the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are effectively retained within the business rather than distributed to shareholders. Consequently, the overall growth and income profile is characterized by a lack of current income distribution and a contraction in profitability that outpaces the decline in revenue, presenting a scenario where capital preservation is the primary financial outcome rather than expansion or shareholder yield.